Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 14/20 | 0.62 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.62 |
| ▸ | CYSLTR2 | Q9NS75 | 9/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8734305 | 0.89 | CYSLTR1 (0.61) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7095202 | 0.87 | CYSLTR1 (0.70) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7092083 | 0.81 | CYSLTR1 (0.61) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL10635750 | 0.81 | CYSLTR1 (0.71) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL8506678 | 0.80 | CYSLTR1 (0.72) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL8506505 | 0.80 | CYSLTR1 (0.81) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL10632382 | 0.80 | CYSLTR1 (0.69) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL8321128 | 0.80 | CYSLTR1 (0.76) | CYSLTR1GPBAR1CYSLTR2ALOX5 | |
| SCHEMBL10638992 | 0.79 | CYSLTR1 (0.76) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL15271902 | 0.79 | GPBAR1 (0.77) | CYSLTR1GPBAR1CYSLTR2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888352-B1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2003-05-28 | — | — | EP | disclosed |
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSENS FRANS EDUARD (BE) | 2003-05-08 | — | — | US | disclosed |
| US-6544979-B1 | Having multidrug resistance modulating properties | JANSSEN PHARMACEUTICALS, N.V. (BE) | 2003-04-08 | — | — | US | disclosed |
| EP-1011726-B1 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA NV (BE) | 2003-02-26 | — | — | EP | disclosed |
| US-6476018-B1 | Fused imidazole derivatives as multidrug resistance modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-11-05 | — | — | US | disclosed |
| US-6218381-B1 | FOR DECREASING, ELIMINATING OR REVERSING A DEVELOPING OR EXISTING RESISTANCE TO CHEMOTHERAPEUTIC DRUG THERAPY | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-04-17 | — | — | US | disclosed |
| EP-1011726-A2 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999013871-A2 | FUSED IMIDAZOLE DERIVATIVES FOR IMPROVING ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-03-25 | — | — | WO | disclosed |
| EP-0888352-A1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034897-A1 | FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG RESISTANCE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087895-A1 | Fused imidazole derivatives as multidrug resistance modulators | ABCC1, CBR1, ABCB11 | CYSLTR1 491/4885GPBAR1 60/4885CYSLTR2 807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.